06.12.2016 16:58
Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, today announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of NI-0101, a monoclonal antibody, for the potential treatment of rheumatoid arthritis and other autoimmune diseases.